Untreatable Bacteria—A Silent Pandemic

Close-up of a keyboard key labeled 'ANTIBIOTIC RESISTANCE' in bold red letters

Infection rates from drug-resistant “nightmare bacteria” are climbing, posing a grave threat to public health and challenging antibiotic effectiveness.

Story Highlights

CDC reports a nearly 70% rise in “nightmare bacteria” cases since 2019.
These bacteria resist nearly all available antibiotics, complicating treatments.
The COVID-19 pandemic contributed significantly to this increase.
Urgent need for improved antibiotic stewardship and infection control.

Rising Threat of Drug-Resistant Bacteria

According to the Centers for Disease Control and Prevention (CDC), infection rates from drug-resistant bacteria, often called “nightmare bacteria,” have surged nearly 70% from 2019 to 2023. This dramatic increase underscores a growing public health crisis as these bacteria are resistant to nearly all available antibiotics, making infections extremely difficult to treat. The CDC attributes this alarming rise to factors such as antibiotic misuse and the spread of resistance genes like New Delhi metallo-beta-lactamase (NDM).

Infection rates from drug-resistant “nightmare bacteria” rose almost 70% between 2019 and 2023, according to a new report from CDC scientists. https://t.co/CnQxCqHMXm

— WWJ 950 (@WWJ950) September 23, 2025

The COVID-19 pandemic has exacerbated the issue, with a 20% increase in hospital-onset resistant infections between 2020 and 2022. This surge peaked in 2021 and remained above pre-pandemic levels into 2022. The pandemic led to increased antibiotic use, often inappropriately, reduced infection control measures, and overwhelmed healthcare systems, all contributing to a surge in resistant infections.

Limited Treatment Options and Consequences

Compounding the crisis, only two expensive IV antibiotics remain effective against some strains of these resistant bacteria. This limitation in treatment options poses a significant threat to healthcare, especially for patients with weakened immune systems or frequent healthcare exposure. Hospitals are on the front lines, grappling with infection control and antibiotic stewardship amidst resource constraints.

The economic impact is equally daunting, with the cost of treating resistant infections in the U.S. exceeding $4.6 billion annually. This financial strain, coupled with the social anxiety over untreatable infections, places immense pressure on policymakers for increased funding and regulatory action to curb this public health threat.

Urgent Need for Action and Innovation

The emergence of resistance genes, such as NDM, previously rare in the U.S., highlights the urgent need for improved antibiotic stewardship and infection control. The CDC has been vocal about the pressing need for intervention, emphasizing that the window for effective action is narrowing. Public health experts warn that without new antibiotics and better infection control, this crisis will only worsen.

'Nightmare bacteria' cases are increasing in the US https://t.co/HRi07YTSN0

— KSAT 12 (@ksatnews) September 23, 2025

With infection rates remaining well above pre-pandemic levels, the CDC’s targeted interventions have only managed to limit the spread partially. The broader healthcare sector must invest in surveillance, infection control, and stewardship programs to address this escalating threat effectively. The pharmaceutical industry, too, faces challenges in developing new antibiotics due to low profitability, necessitating innovative incentives for drug development.